Where to be

Here's what events to attend each day during The Houston Innovation Summit

Houston startup development organizations have banded together for the third annual Houston Innovation Summit. Getty Images

For the third year, The Houston Innovation Summit is taking over the town to promote entrepreneurship and innovation within the city.

THIS begins today and runs through the weekend. Each day represents a theme — all pertinent to Houston. Impact Hub Houston has worked with other local startup development organizations to curate the programming for the week. Grace Rodriguez, CEO and executive director for Impact Hub Houston, says Houston has the innovation infrastructure by now, and now it's about execution.

"For 2019, the goal is now how do we go from inclusion to integration," Rodriguez says on a recent episode of the Houston Innovators Podcast. "I think we're at that step now of becoming more inclusive as a community."

THIS, just like last year, runs on the same week of Global Entrepreneurship Week, which is why today's programming starts with a global focus. Follow along on a global scale with #GEWecosystems.

For a complete list of THIS events (most of which are free and all over town), head to the website. Here are the events you should make sure not to miss.

Monday — Houston: We're Global

Starting strong, the first can't-miss event is the kickoff party. The free event is in the Amegy Building downtown (1801 Main Street), which is currently being transformed into The Cannon Houston's new Launch Pad. The event runs from 4 to 5:45 pm, and you can expect networking and interactive discussions on Houston's innovation ecosystem's growth and potential. Click here to register.

Tuesday: This Is Houston

While GotSpot's Female Founder Luncheon at MassChallenge is a good one to make if you can, the big event this day is Houston Exponential's 2020 Vision event. Basically an open house-style event, attendees at this free event can learn how to engage with HX and what the organization has planned for 2020. InnovationMap and Accenture are teaming up for a fireside chat about the diversity and potential in Houston. Click here to register.

Wednesday: Fresh Perspectives

The fight for technology and innovation is on. The first Houston Digital Fight Club is on Wednesday, November 20, and will feature five fights between industry experts on topics like cybersecurity, sustainable energy, primary care, and more. Audience members get to decide on a winner, and there will be tons of opportunities for networking. The event is $30 per person and will be at White Oak Music Hall. InnovationMap and Accenture are the lead sponsors. Click here to register.

If you can't make this evening event, WeWork Food Labs is cooking up a special event to discuss food innovation in Houston. Click here to register.

Thursday: The Next Generation

While the week so far has been centered around the future of Houston, Thursday focuses specifically on the next generation of people who will be powering the ecosystem. And, of course, money is essential to that equation. Join for a panel from top investor leaders at an event focused on next generation investing at HCC SouthEast Felix Fraga Academic Campus - East End. The panel itself is $5, but for $15 you can also catch two other discussions on campus that day. Click here to register.

For an early bird alternative, Mercury Fund is hosting a Female Founders breakfast at 7:30 am at their office (3737 Buffalo Speedway, Suite 1750). This one is free to attend. Click here to register.

Friday: Integrating Innovation

Friday's events all take place at The Cannon Houston (1334 Brittmoore Road), and there's a specific focus on military technology and military-affiliated entrepreneurs. The Southwest Muster Across America Tour in Houston is from 1 to 6 pm and will consist of an expo, pitch competition, expert talks, and more. The WeWork Veterans in Residence Program Powered by Bunker Labs will show off their companies, and Bunker Labs has teamed up with Ford Fund to host pitch competitions for veteran and military spouse entrepreneurs. Houston is one of seven stops for the competition, and the top two showcase pitches will win $5,000 and $3,500 from the Ford Fund to help support their businesses. Click here to register.

Following this event is Impact Hub's monthly Fuckup Night, where entrepreneurs share their stories of success, struggle, and failure. Click here to register.

Weekend: Innovation Education

The week wraps up with events focusing on education. One not to miss is on Saturday: The HCC IDEAS Pitch Competition. The competition begins at 1 pm and there is $2,500 on the line. Any HCC student is able to apply to pitch. Click here to register.

Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News